629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
Year: 2020
Type: article
Source: Annals of Oncology
Institutions: Erasmus MC Cancer Institute, Asklepios, Asklepios Kliniken Hamburg, Hospital Universitario 12 De Octubre, Medical University of Vienna, Institut Jean Godinot, Weill Cornell Medicine, Université Paris-Sud, Institut Gustave Roussy, UCLouvain, National and Kapodistrian University of Athens, Alexandra Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Agostino Gemelli University Polyclinic, Azienda Ospedaliera Universitaria Integrata Verona, Palacký University Olomouc, National University Hospital of Iceland, Hôpital Foch, Hôpital d'Instruction des Armées Bégin, Sanofi (United States), Sanofi (France), Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Sanofi
OpenAlex ID: W3088647179